#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-11	Prospective	_
1-2	12-19	Changes	_
1-3	20-22	in	_
1-4	23-29	Neural	_
1-5	30-37	Alcohol	_
1-6	38-41	Cue	_
1-7	42-52	Reactivity	_
1-8	53-55	in	_
1-9	56-63	At-Risk	_
1-10	64-75	Adolescents	_
1-11	76-88	Introduction	_
1-12	89-100	Adolescence	_
1-13	101-111	represents	_
1-14	112-114	an	_
1-15	115-120	ideal	_
1-16	121-125	time	_
1-17	126-129	for	_
1-18	130-141	elucidating	_
1-19	142-145	the	_
1-20	146-154	etiology	_
1-21	155-157	of	_
1-22	158-161	cue	_
1-23	162-172	reactivity	_
1-24	173-181	profiles	_
1-25	182-183	.	_

2-1	184-188	This	_
2-2	189-194	study	_
2-3	195-203	examined	_
2-4	204-207	the	_
2-5	208-217	influence	_
2-6	218-220	of	_
2-7	221-226	three	_
2-8	227-231	risk	_
2-9	232-239	factors	_
2-10	240-252	consistently	_
2-11	253-263	associated	_
2-12	264-268	with	_
2-13	269-274	heavy	_
2-14	275-285	adolescent	_
2-15	286-294	drinking	_
2-16	295-297	on	_
2-17	298-305	alcohol	_
2-18	306-309	cue	_
2-19	310-320	reactivity	_
2-20	321-322	.	_

3-1	323-330	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
3-2	331-336	Youth	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
3-3	337-341	were	_
3-4	342-347	first	_
3-5	348-356	assessed	_
3-6	357-362	while	_
3-7	363-368	still	_
3-8	369-374	naïve	_
3-9	375-377	to	_
3-10	378-385	alcohol	_
3-11	386-387	(	_
3-12	388-393	12–14	_
3-13	394-399	years	_
3-14	400-403	old	_
3-15	404-405	)	_
3-16	406-409	and	_
3-17	410-418	followed	_
3-18	419-424	after	_
3-19	425-438	transitioning	_
3-20	439-443	into	_
3-21	444-451	alcohol	_
3-22	452-455	use	_
3-23	456-457	(	_
3-24	458-463	17–21	_
3-25	464-469	years	_
3-26	470-473	old	_
3-27	474-475	)	_
3-28	476-477	.	_

4-1	478-481	The	_
4-2	482-489	effects	_
4-3	490-492	of	_
4-4	493-499	family	_
4-5	500-507	history	_
4-6	508-510	of	_
4-7	511-520	substance	_
4-8	521-524	use	_
4-9	525-533	disorder	_
4-10	534-535	,	_
4-11	536-539	sex	_
4-12	540-541	,	_
4-13	542-545	and	_
4-14	546-553	history	_
4-15	554-556	of	_
4-16	557-562	early	_
4-17	563-565	of	_
4-18	566-572	dating	_
4-19	573-574	(	_
4-20	575-579	i.e.	_
4-21	580-581	,	_
4-22	582-588	before	_
4-23	589-591	14	_
4-24	592-597	years	_
4-25	598-600	of	_
4-26	601-604	age	_
4-27	605-606	)	_
4-28	607-609	on	_
4-29	610-614	BOLD	_
4-30	615-623	response	_
4-31	624-632	contrast	_
4-32	633-635	to	_
4-33	636-643	alcohol	_
4-34	644-651	picture	_
4-35	652-656	cues	_
4-36	657-661	were	_
4-37	662-670	examined	_
4-38	671-673	in	_
4-39	674-675	a	_
4-40	676-682	linear	_
4-41	683-688	mixed	_
4-42	689-694	model	_
4-43	695-696	,	_
4-44	697-708	controlling	_
4-45	709-712	for	_
4-46	713-716	age	_
4-47	717-720	and	_
4-48	721-728	alcohol	_
4-49	729-732	use	_
4-50	733-741	patterns	_
4-51	742-744	at	_
4-52	745-754	follow-up	_
4-53	755-756	.	_

5-1	757-763	Result	_
5-2	764-774	Activation	_
5-3	775-777	to	_
5-4	778-785	alcohol	_
5-5	786-793	picture	_
5-6	794-798	cues	_
5-7	799-807	differed	_
5-8	808-810	as	_
5-9	811-812	a	_
5-10	813-821	function	_
5-11	822-824	of	_
5-12	825-829	risk	_
5-13	830-836	factor	_
5-14	837-840	and	_
5-15	841-845	time	_
5-16	846-847	.	_

6-1	848-850	At	_
6-2	851-859	baseline	_
6-3	860-861	,	_
6-4	862-868	family	_
6-5	869-876	history	_
6-6	877-885	positive	_
6-7	886-891	youth	_
6-8	892-898	showed	_
6-9	899-906	greater	_
6-10	907-917	activation	_
6-11	918-920	to	_
6-12	921-928	alcohol	_
6-13	929-933	cues	_
6-14	934-938	than	_
6-15	939-945	family	_
6-16	946-953	history	_
6-17	954-962	negative	_
6-18	963-968	peers	_
6-19	969-971	in	_
6-20	972-975	the	_
6-21	976-981	right	_
6-22	982-988	middle	_
6-23	989-998	occipital	_
6-24	999-1002	and	_
6-25	1003-1011	anterior	_
6-26	1012-1021	cingulate	_
6-27	1022-1026	gyri	_
6-28	1027-1028	.	_

7-1	1029-1034	Youth	http://maven.renci.org/NeuroBridge/neurobridge#StudyOutcome
7-2	1035-1039	with	_
7-3	1040-1041	a	_
7-4	1042-1049	history	_
7-5	1050-1052	of	_
7-6	1053-1065	early-dating	_
7-7	1066-1072	showed	_
7-8	1073-1080	greater	_
7-9	1081-1091	activation	_
7-10	1092-1094	to	_
7-11	1095-1102	alcohol	_
7-12	1103-1107	cues	_
7-13	1108-1109	,	_
7-14	1110-1118	compared	_
7-15	1119-1121	to	_
7-16	1122-1131	non-early	_
7-17	1132-1138	daters	_
7-18	1139-1140	,	_
7-19	1141-1143	in	_
7-20	1144-1147	the	_
7-21	1148-1152	left	_
7-22	1153-1161	anterior	_
7-23	1162-1177	cingulate/white	_
7-24	1178-1184	matter	_
7-25	1185-1191	region	_
7-26	1192-1193	.	_

8-1	1194-1199	Girls	_
8-2	1200-1206	showed	_
8-3	1207-1214	greater	_
8-4	1215-1225	activation	_
8-5	1226-1228	to	_
8-6	1229-1236	alcohol	_
8-7	1237-1241	than	_
8-8	1242-1246	boys	_
8-9	1247-1249	at	_
8-10	1250-1258	baseline	_
8-11	1259-1261	in	_
8-12	1262-1266	left	_
8-13	1267-1273	middle	_
8-14	1274-1281	frontal	_
8-15	1282-1287	gyrus	_
8-16	1288-1289	.	_

9-1	1290-1292	At	_
9-2	1293-1302	follow-up	_
9-3	1303-1304	,	_
9-4	1305-1310	after	_
9-5	1311-1319	drinking	_
9-6	1320-1327	started	_
9-7	1328-1329	,	_
9-8	1330-1338	patterns	_
9-9	1339-1347	reversed	_
9-10	1348-1351	for	_
9-11	1352-1356	each	_
9-12	1357-1361	risk	_
9-13	1362-1368	factor	_
9-14	1369-1370	.	_

10-1	1371-1381	Discussion	_
10-2	1382-1387	These	_
10-3	1388-1395	results	_
10-4	1396-1404	indicate	_
10-5	1405-1409	that	_
10-6	1410-1414	even	_
10-7	1415-1420	prior	_
10-8	1421-1423	to	_
10-9	1424-1434	initiating	_
10-10	1435-1442	alcohol	_
10-11	1443-1446	use	_
10-12	1447-1448	,	_
10-13	1449-1460	adolescents	_
10-14	1461-1467	showed	_
10-15	1468-1479	differences	_
10-16	1480-1482	in	_
10-17	1483-1493	activation	_
10-18	1494-1496	to	_
10-19	1497-1504	alcohol	_
10-20	1505-1509	cues	_
10-21	1510-1515	based	_
10-22	1516-1518	on	_
10-23	1519-1524	their	_
10-24	1525-1531	family	_
10-25	1532-1539	history	_
10-26	1540-1541	,	_
10-27	1542-1548	dating	_
10-28	1549-1556	history	_
10-29	1557-1558	,	_
10-30	1559-1562	and	_
10-31	1563-1566	sex	_
10-32	1567-1568	.	_

11-1	1569-1576	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
11-2	1577-1589	Participants	_
11-3	1590-1594	This	_
11-4	1595-1600	study	_
11-5	1601-1605	used	_
11-6	1606-1610	data	_
11-7	1611-1615	from	_
11-8	1616-1617	a	_
11-9	1618-1624	larger	_
11-10	1625-1632	ongoing	_
11-11	1633-1645	longitudinal	_
11-12	1646-1655	substance	_
11-13	1656-1659	use	_
11-14	1660-1663	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
11-15	1664-1676	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
11-16	1677-1684	project	_
11-17	1685-1686	(	_
11-18	1687-1690	R01	_
11-19	1691-1698	AA13419	_
11-20	1699-1700	)	_
11-21	1701-1702	,	_
11-22	1703-1704	a	_
11-23	1705-1713	protocol	_
11-24	1714-1718	that	_
11-25	1719-1722	was	_
11-26	1723-1731	approved	_
11-27	1732-1734	by	_
11-28	1735-1738	the	_
11-29	1739-1749	University	_
11-30	1750-1752	of	_
11-31	1753-1763	California	_
11-32	1764-1767	San	_
11-33	1768-1773	Diego	_
11-34	1774-1779	Human	_
11-35	1780-1788	Research	_
11-36	1789-1800	Protections	_
11-37	1801-1808	Program	_
11-38	1809-1810	.	_

12-1	1811-1823	Participants	_
12-2	1824-1831	between	_
12-3	1832-1834	12	_
12-4	1835-1837	to	_
12-5	1838-1840	14	_
12-6	1841-1846	years	_
12-7	1847-1850	old	_
12-8	1851-1855	were	_
12-9	1856-1865	recruited	_
12-10	1866-1870	from	_
12-11	1871-1874	San	_
12-12	1875-1880	Diego	_
12-13	1881-1887	public	_
12-14	1888-1894	middle	_
12-15	1895-1902	schools	_
12-16	1903-1904	.	_

13-1	1905-1913	Eligible	_
13-2	1914-1919	youth	_
13-3	1920-1921	(	_
13-4	1922-1923	N	_
13-5	1924-1925	=	_
13-6	1926-1929	295	_
13-7	1930-1931	)	_
13-8	1932-1936	were	_
13-9	1937-1949	administered	_
13-10	1950-1951	a	_
13-11	1952-1965	comprehensive	_
13-12	1966-1975	interview	_
13-13	1976-1985	assessing	_
13-14	1986-1995	substance	_
13-15	1996-1999	use	_
13-16	2000-2003	and	_
13-17	2004-2015	demographic	_
13-18	2016-2027	information	_
13-19	2028-2029	(	_
13-20	2030-2034	e.g.	_
13-21	2035-2036	,	_
13-22	2037-2040	age	_
13-23	2041-2042	,	_
13-24	2043-2052	ethnicity	_
13-25	2053-2054	)	_
13-26	2055-2058	and	_
13-27	2059-2068	completed	_
13-28	2069-2071	an	_
13-29	2072-2075	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
13-30	2076-2080	scan	_
13-31	2081-2083	at	_
13-32	2084-2092	baseline	_
13-33	2093-2094	(	_
13-34	2095-2102	project	_
13-35	2103-2108	entry	_
13-36	2109-2110	)	_
13-37	2111-2112	.	_

14-1	2113-2115	In	_
14-2	2116-2119	the	_
14-3	2120-2126	parent	_
14-4	2127-2132	study	_
14-5	2133-2134	,	_
14-6	2135-2144	potential	_
14-7	2145-2157	participants	_
14-8	2158-2162	were	_
14-9	2163-2171	excluded	_
14-10	2172-2175	for	_
14-11	2176-2187	psychiatric	_
14-12	2188-2197	diagnoses	_
14-13	2198-2199	,	_
14-14	2200-2218	neurodevelopmental	_
14-15	2219-2228	disorders	_
14-16	2229-2230	,	_
14-17	2231-2234	and	_
14-18	2235-2238	use	_
14-19	2239-2243	that	_
14-20	2244-2252	exceeded	_
14-21	2253-2260	minimal	_
14-22	2261-2269	exposure	_
14-23	2270-2272	to	_
14-24	2273-2280	alcohol	_
14-25	2281-2284	and	_
14-26	2285-2290	other	_
14-27	2291-2301	substances	_
14-28	2302-2303	.	_

15-1	2304-2316	Participants	_
15-2	2317-2321	were	_
15-3	2322-2333	followed-up	_
15-4	2334-2338	each	_
15-5	2339-2343	year	_
15-6	2344-2346	by	_
15-7	2347-2352	phone	_
15-8	2353-2355	to	_
15-9	2356-2362	obtain	_
15-10	2363-2367	data	_
15-11	2368-2373	about	_
15-12	2374-2381	alcohol	_
15-13	2382-2393	consumption	_
15-14	2394-2397	and	_
15-15	2398-2403	other	_
15-16	2404-2408	drug	_
15-17	2409-2412	use	_
15-18	2413-2419	habits	_
15-19	2420-2423	and	_
15-20	2424-2436	psychosocial	_
15-21	2437-2444	changes	_
15-22	2445-2446	(	_
15-23	2447-2451	e.g.	_
15-24	2452-2453	,	_
15-25	2454-2459	grade	_
15-26	2460-2462	in	_
15-27	2463-2469	school	_
15-28	2470-2471	)	_
15-29	2472-2473	.	_

16-1	2474-2485	Individuals	_
16-2	2486-2489	who	_
16-3	2490-2502	transitioned	_
16-4	2503-2507	into	_
16-5	2508-2516	drinking	_
16-6	2517-2521	were	_
16-7	2522-2529	brought	_
16-8	2530-2534	back	_
16-9	2535-2539	into	_
16-10	2540-2543	the	_
16-11	2544-2554	laboratory	_
16-12	2555-2558	for	_
16-13	2559-2560	a	_
16-14	2561-2567	repeat	_
16-15	2568-2571	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
16-16	2572-2576	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
16-17	2577-2579	at	_
16-18	2580-2589	follow-up	_
16-19	2590-2591	.	_

17-1	2592-2595	Not	_
17-2	2596-2599	all	_
17-3	2600-2612	participants	_
17-4	2613-2615	in	_
17-5	2616-2619	the	_
17-6	2620-2626	parent	_
17-7	2627-2632	study	_
17-8	2633-2641	received	_
17-9	2642-2645	the	_
17-10	2646-2653	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
17-11	2654-2662	Pictures	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
17-12	2663-2666	Cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
17-13	2667-2677	Reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
17-14	2678-2682	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
17-15	2683-2684	,	_
17-16	2685-2687	as	_
17-17	2688-2690	it	_
17-18	2691-2694	was	_
17-19	2695-2700	added	_
17-20	2701-2706	later	_
17-21	2707-2713	during	_
17-22	2714-2717	the	_
17-23	2718-2725	project	_
17-24	2726-2727	.	_

18-1	2728-2731	The	_
18-2	2732-2738	sample	_
18-3	2739-2742	for	_
18-4	2743-2746	the	_
18-5	2747-2754	current	_
18-6	2755-2760	study	_
18-7	2761-2769	included	_
18-8	2770-2774	only	_
18-9	2775-2780	those	_
18-10	2781-2793	participants	_
18-11	2794-2796	in	_
18-12	2797-2800	the	_
18-13	2801-2807	parent	_
18-14	2808-2813	study	_
18-15	2814-2817	who	_
18-16	2818-2822	were	_
18-17	2823-2835	administered	_
18-18	2836-2840	this	_
18-19	2841-2845	task	_
18-20	2846-2848	at	_
18-21	2849-2857	baseline	_
18-22	2858-2861	and	_
18-23	2862-2871	follow-up	_
18-24	2872-2873	.	_

19-1	2874-2876	To	_
19-2	2877-2884	account	_
19-3	2885-2888	for	_
19-4	2889-2897	possible	_
19-5	2898-2905	effects	_
19-6	2906-2908	of	_
19-7	2909-2914	prior	_
19-8	2915-2922	alcohol	_
19-9	2923-2926	and	_
19-10	2927-2932	other	_
19-11	2933-2942	substance	_
19-12	2943-2946	use	_
19-13	2947-2949	on	_
19-14	2950-2953	cue	_
19-15	2954-2964	reactivity	_
19-16	2965-2967	at	_
19-17	2968-2976	baseline	_
19-18	2977-2978	,	_
19-19	2979-2991	participants	_
19-20	2992-2994	in	_
19-21	2995-2998	the	_
19-22	2999-3005	parent	_
19-23	3006-3011	study	_
19-24	3012-3015	who	_
19-25	3016-3024	reported	_
19-26	3025-3031	having	_
19-27	3032-3035	any	_
19-28	3036-3046	experience	_
19-29	3047-3051	with	_
19-30	3052-3059	alcohol	_
19-31	3060-3067	greater	_
19-32	3068-3072	than	_
19-33	3073-3080	several	_
19-34	3081-3085	sips	_
19-35	3086-3089	and	_
19-36	3090-3093	any	_
19-37	3094-3101	history	_
19-38	3102-3104	of	_
19-39	3105-3110	other	_
19-40	3111-3120	substance	_
19-41	3121-3124	use	_
19-42	3125-3127	at	_
19-43	3128-3135	project	_
19-44	3136-3142	intake	_
19-45	3143-3147	were	_
19-46	3148-3156	excluded	_
19-47	3157-3161	from	_
19-48	3162-3170	analysis	_
19-49	3171-3172	.	_

20-1	3173-3181	Likewise	_
20-2	3182-3183	,	_
20-3	3184-3186	to	_
20-4	3187-3194	examine	_
20-5	3195-3198	the	_
20-6	3199-3206	effects	_
20-7	3207-3209	of	_
20-8	3210-3220	initiation	_
20-9	3221-3223	of	_
20-10	3224-3231	alcohol	_
20-11	3232-3235	use	_
20-12	3236-3238	on	_
20-13	3239-3246	alcohol	_
20-14	3247-3250	cue	_
20-15	3251-3261	reactivity	_
20-16	3262-3263	,	_
20-17	3264-3276	participants	_
20-18	3277-3280	who	_
20-19	3281-3284	had	_
20-20	3285-3288	not	_
20-21	3289-3298	initiated	_
20-22	3299-3306	alcohol	_
20-23	3307-3310	use	_
20-24	3311-3313	at	_
20-25	3314-3323	follow-up	_
20-26	3324-3325	(	_
20-27	3326-3330	i.e.	_
20-28	3331-3332	,	_
20-29	3333-3337	have	_
20-30	3338-3341	not	_
20-31	3342-3345	had	_
20-32	3346-3348	at	_
20-33	3349-3354	least	_
20-34	3355-3358	one	_
20-35	3359-3367	standard	_
20-36	3368-3373	drink	_
20-37	3374-3375	)	_
20-38	3376-3380	were	_
20-39	3381-3385	also	_
20-40	3386-3394	excluded	_
20-41	3395-3399	from	_
20-42	3400-3408	analysis	_
20-43	3409-3410	.	_

21-1	3411-3413	In	_
21-2	3414-3419	total	_
21-3	3420-3421	,	_
21-4	3422-3424	51	_
21-5	3425-3437	participants	_
21-6	3438-3441	met	_
21-7	3442-3450	criteria	_
21-8	3451-3454	for	_
21-9	3455-3465	inclusions	_
21-10	3466-3468	in	_
21-11	3469-3472	the	_
21-12	3473-3480	current	_
21-13	3481-3484	set	_
21-14	3485-3487	of	_
21-15	3488-3496	analyses	_
21-16	3497-3498	.	_

22-1	3499-3507	Measures	http://maven.renci.org/NeuroBridge/neurobridge#ReportedMeasurement
22-2	3508-3518	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-3	3519-3527	clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-4	3528-3537	interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-5	3538-3541	The	_
22-6	3542-3552	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-7	3553-3561	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-8	3562-3571	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-9	3572-3575	was	_
22-10	3576-3588	administered	_
22-11	3589-3591	to	_
22-12	3592-3597	youth	_
22-13	3598-3600	at	_
22-14	3601-3609	baseline	_
22-15	3610-3613	and	_
22-16	3614-3623	follow-up	_
22-17	3624-3626	to	_
22-18	3627-3633	assess	_
22-19	3634-3641	general	_
22-20	3642-3654	psychosocial	_
22-21	3655-3666	functioning	_
22-22	3667-3671	such	_
22-23	3672-3674	as	_
22-24	3675-3683	academic	_
22-25	3684-3695	functioning	_
22-26	3696-3697	(	_
22-27	3698-3702	e.g.	_
22-28	3703-3704	,	_
22-29	3705-3710	grade	_
22-30	3711-3716	point	_
22-31	3717-3724	average	_
22-32	3725-3726	)	_
22-33	3727-3730	and	_
22-34	3731-3735	peer	_
22-35	3736-3745	relations	_
22-36	3746-3749	and	_
22-37	3750-3759	attitudes	_
22-38	3760-3767	towards	_
22-39	3768-3777	substance	_
22-40	3778-3781	use	_
22-41	3782-3783	,	_
22-42	3784-3787	and	_
22-43	3788-3793	major	_
22-44	3794-3801	medical	_
22-45	3802-3811	illnesses	_
22-46	3812-3813	.	_

23-1	3814-3820	Dating	_
23-2	3821-3827	status	_
23-3	3828-3831	was	_
23-4	3832-3839	defined	_
23-5	3840-3853	dichotomously	_
23-6	3854-3858	with	_
23-7	3859-3862	the	_
23-8	3863-3871	question	_
23-9	3872-3873	“	_
23-10	3874-3876	Do	_
23-11	3877-3880	you	_
23-12	3881-3885	date	_
23-13	3886-3887	”	_
23-14	3888-3890	at	_
23-15	3891-3899	baseline	_
23-16	3900-3901	.	_

24-1	3902-3908	Answer	_
24-2	3909-3916	choices	_
24-3	3917-3921	were	_
24-4	3922-3923	“	_
24-5	3924-3926	no	_
24-6	3927-3928	,	_
24-7	3929-3934	never	_
24-8	3935-3940	dated	_
24-9	3941-3942	”	_
24-10	3943-3944	,	_
24-11	3945-3946	“	_
24-12	3947-3949	no	_
24-13	3950-3951	,	_
24-14	3952-3955	not	_
24-15	3956-3959	now	_
24-16	3960-3961	”	_
24-17	3962-3963	,	_
24-18	3964-3965	“	_
24-19	3966-3969	yes	_
24-20	3970-3971	,	_
24-21	3972-3976	only	_
24-22	3977-3979	in	_
24-23	3980-3985	group	_
24-24	3986-3996	activities	_
24-25	3997-3998	”	_
24-26	3999-4000	,	_
24-27	4001-4002	“	_
24-28	4003-4006	yes	_
24-29	4007-4008	,	_
24-30	4009-4015	rarely	_
24-31	4016-4017	”	_
24-32	4018-4019	,	_
24-33	4020-4021	“	_
24-34	4022-4025	yes	_
24-35	4026-4027	,	_
24-36	4028-4040	occasionally	_
24-37	4041-4042	”	_
24-38	4043-4044	,	_
24-39	4045-4046	“	_
24-40	4047-4050	yes	_
24-41	4051-4052	,	_
24-42	4053-4062	regularly	_
24-43	4063-4064	”	_
24-44	4065-4066	,	_
24-45	4067-4068	“	_
24-46	4069-4072	yes	_
24-47	4073-4074	,	_
24-48	4075-4081	steady	_
24-49	4082-4089	partner	_
24-50	4090-4091	”	_
24-51	4092-4093	,	_
24-52	4094-4096	or	_
24-53	4097-4098	“	_
24-54	4099-4100	I	_
24-55	4101-4103	am	_
24-56	4104-4112	married.	_
24-57	4113-4114	”	_
24-58	4115-4117	At	_
24-59	4118-4126	baseline	_
24-60	4127-4128	,	_
24-61	4129-4134	youth	_
24-62	4135-4139	were	_
24-63	4140-4145	coded	_
24-64	4146-4148	as	_
24-65	4149-4155	either	_
24-66	4156-4157	1	_
24-67	4158-4159	)	_
24-68	4160-4169	non-early	_
24-69	4170-4176	daters	_
24-70	4177-4178	(	_
24-71	4179-4183	i.e.	_
24-72	4184-4185	,	_
24-73	4186-4188	no	_
24-74	4189-4196	history	_
24-75	4197-4199	of	_
24-76	4200-4206	dating	_
24-77	4207-4208	)	_
24-78	4209-4211	if	_
24-79	4212-4216	they	_
24-80	4217-4225	answered	_
24-81	4226-4227	“	_
24-82	4228-4230	no	_
24-83	4231-4232	,	_
24-84	4233-4238	never	_
24-85	4239-4244	dated	_
24-86	4245-4246	”	_
24-87	4247-4248	,	_
24-88	4249-4251	or	_
24-89	4252-4253	2	_
24-90	4254-4255	)	_
24-91	4256-4261	early	_
24-92	4262-4268	daters	_
24-93	4269-4270	(	_
24-94	4271-4275	i.e.	_
24-95	4276-4277	,	_
24-96	4278-4282	have	_
24-97	4283-4284	a	_
24-98	4285-4292	history	_
24-99	4293-4295	of	_
24-100	4296-4299	any	_
24-101	4300-4301	,	_
24-102	4302-4304	or	_
24-103	4305-4308	are	_
24-104	4309-4318	currently	_
24-105	4319-4320	,	_
24-106	4321-4327	dating	_
24-107	4328-4329	)	_
24-108	4330-4332	if	_
24-109	4333-4341	answered	_
24-110	4342-4351	otherwise	_
24-111	4352-4353	.	_

25-1	4354-4357	All	_
25-2	4358-4361	but	_
25-3	4362-4365	one	_
25-4	4366-4377	participant	_
25-5	4378-4386	reported	_
25-6	4387-4393	having	_
25-7	4394-4399	dated	_
25-8	4400-4402	at	_
25-9	4403-4408	least	_
25-10	4409-4413	once	_
25-11	4414-4416	at	_
25-12	4417-4426	follow-up	_
25-13	4427-4428	.	_

26-1	4429-4438	Substance	_
26-2	4439-4442	use	_
26-3	4443-4446	The	_
26-4	4447-4456	Customary	http://maven.renci.org/NeuroBridge/neurobridge#Kleptomania
26-5	4457-4465	Drinking	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
26-6	4466-4469	and	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
26-7	4470-4474	Drug	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
26-8	4475-4478	Use	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
26-9	4479-4485	Record	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
26-10	4486-4489	was	_
26-11	4490-4502	administered	_
26-12	4503-4505	at	_
26-13	4506-4514	baseline	_
26-14	4515-4518	and	_
26-15	4519-4528	follow-up	_
26-16	4529-4534	years	_
26-17	4535-4537	to	_
26-18	4538-4544	assess	_
26-19	4545-4550	onset	_
26-20	4551-4552	,	_
26-21	4553-4562	frequency	_
26-22	4563-4564	,	_
26-23	4565-4573	quantity	_
26-24	4574-4575	,	_
26-25	4576-4579	and	_
26-26	4580-4588	sequelae	_
26-27	4589-4591	of	_
26-28	4592-4599	alcohol	_
26-29	4600-4603	and	_
26-30	4604-4609	other	_
26-31	4610-4619	substance	_
26-32	4620-4623	use	_
26-33	4624-4625	.	_

27-1	4626-4638	Participants	_
27-2	4639-4643	were	_
27-3	4644-4649	asked	_
27-4	4650-4652	to	_
27-5	4653-4660	abstain	_
27-6	4661-4665	from	_
27-7	4666-4673	alcohol	_
27-8	4674-4677	and	_
27-9	4678-4690	recreational	_
27-10	4691-4695	drug	_
27-11	4696-4699	use	_
27-12	4700-4703	for	_
27-13	4704-4706	72	_
27-14	4707-4712	hours	_
27-15	4713-4718	prior	_
27-16	4719-4721	to	_
27-17	4722-4726	scan	_
27-18	4727-4735	sessions	_
27-19	4736-4737	.	_

28-1	4738-4750	Breathalyzer	_
28-2	4751-4754	and	_
28-3	4755-4760	urine	_
28-4	4761-4771	toxicology	_
28-5	4772-4779	screens	_
28-6	4780-4784	were	_
28-7	4785-4797	administered	_
28-8	4798-4800	in	_
28-9	4801-4804	the	_
28-10	4805-4815	laboratory	_
28-11	4816-4818	to	_
28-12	4819-4826	confirm	_
28-13	4827-4833	recent	_
28-14	4834-4844	abstinence	_
28-15	4845-4846	.	_

29-1	4847-4853	Family	_
29-2	4854-4861	history	_
29-3	4862-4865	The	_
29-4	4866-4872	Family	_
29-5	4873-4880	History	_
29-6	4881-4891	Assessment	_
29-7	4892-4898	Module	_
29-8	4899-4902	was	_
29-9	4903-4915	administered	_
29-10	4916-4918	to	_
29-11	4919-4924	youth	_
29-12	4925-4928	and	_
29-13	4929-4933	both	_
29-14	4934-4941	parents	_
29-15	4942-4943	,	_
29-16	4944-4946	or	_
29-17	4947-4950	one	_
29-18	4951-4957	parent	_
29-19	4958-4961	and	_
29-20	4962-4969	another	_
29-21	4970-4976	family	_
29-22	4977-4983	member	_
29-23	4984-4985	,	_
29-24	4986-4988	to	_
29-25	4989-4995	assess	_
29-26	4996-5004	familial	_
29-27	5005-5012	density	_
29-28	5013-5015	of	_
29-29	5016-5023	alcohol	_
29-30	5024-5027	and	_
29-31	5028-5033	other	_
29-32	5034-5043	substance	_
29-33	5044-5047	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
29-34	5048-5057	disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
29-35	5058-5059	(	_
29-36	5060-5063	SUD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
29-37	5064-5065	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
29-38	5066-5067	.	_

30-1	5068-5074	Family	_
30-2	5075-5082	history	_
30-3	5083-5091	negative	_
30-4	5092-5093	(	_
30-5	5094-5097	FHN	_
30-6	5098-5099	)	_
30-7	5100-5103	was	_
30-8	5104-5111	defined	_
30-9	5112-5114	as	_
30-10	5115-5121	having	_
30-11	5122-5124	no	_
30-12	5125-5131	first-	_
30-13	5132-5134	or	_
30-14	5135-5148	second-degree	_
30-15	5149-5157	relative	_
30-16	5158-5162	with	_
30-17	5163-5170	history	_
30-18	5171-5173	of	_
30-19	5174-5177	SUD	_
30-20	5178-5179	,	_
30-21	5180-5186	family	_
30-22	5187-5194	history	_
30-23	5195-5203	positive	_
30-24	5204-5205	(	_
30-25	5206-5209	FHP	_
30-26	5210-5211	)	_
30-27	5212-5214	as	_
30-28	5215-5221	having	_
30-29	5222-5225	one	_
30-30	5226-5228	or	_
30-31	5229-5233	more	_
30-32	5234-5240	first-	_
30-33	5241-5243	or	_
30-34	5244-5257	second-degree	_
30-35	5258-5266	relative	_
30-36	5267-5271	with	_
30-37	5272-5279	history	_
30-38	5280-5282	of	_
30-39	5283-5286	SUD	_
30-40	5287-5288	.	_

31-1	5289-5302	Socioeconomic	http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus
31-2	5303-5309	status	http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus
31-3	5310-5313	The	_
31-4	5314-5326	Hollingshead	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
31-5	5327-5332	Index	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
31-6	5333-5335	of	_
31-7	5336-5342	Social	_
31-8	5343-5351	Position	http://maven.renci.org/NeuroBridge/neurobridge#OppositionalDefiantDisorder
31-9	5352-5357	score	_
31-10	5358-5359	(	_
31-11	5360-5372	Hollingshead	_
31-12	5373-5377	1965	_
31-13	5378-5379	)	_
31-14	5380-5381	,	_
31-15	5382-5384	an	_
31-16	5385-5390	index	_
31-17	5391-5393	of	_
31-18	5394-5407	socioeconomic	_
31-19	5408-5414	status	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus
31-20	5415-5416	(	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus
31-21	5417-5420	SES	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus
31-22	5421-5422	)	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus
31-23	5423-5424	,	_
31-24	5425-5428	was	_
31-25	5429-5439	calculated	_
31-26	5440-5443	for	_
31-27	5444-5448	each	_
31-28	5449-5456	subject	_
31-29	5457-5462	using	_
31-30	5463-5471	parental	_
31-31	5472-5485	socioeconomic	_
31-32	5486-5496	background	_
31-33	5497-5508	information	_
31-34	5509-5510	(	_
31-35	5511-5515	i.e.	_
31-36	5516-5517	,	_
31-37	5518-5529	educational	_
31-38	5530-5540	attainment	_
31-39	5541-5542	,	_
31-40	5543-5553	occupation	_
31-41	5554-5555	,	_
31-42	5556-5559	and	_
31-43	5560-5566	salary	_
31-44	5567-5569	of	_
31-45	5570-5574	each	_
31-46	5575-5581	parent	_
31-47	5582-5583	)	_
31-48	5584-5586	to	_
31-49	5587-5599	characterize	_
31-50	5600-5603	the	_
31-51	5604-5609	youth	_
31-52	5610-5611	’	_
31-53	5612-5613	s	_
31-54	5614-5618	home	_
31-55	5619-5630	environment	_
31-56	5631-5632	.	_

32-1	5633-5639	Higher	_
32-2	5640-5646	values	_
32-3	5647-5655	indicate	_
32-4	5656-5661	lower	_
32-5	5662-5665	SES	_
32-6	5666-5667	.	_

33-1	5668-5675	Imaging	_
33-2	5676-5683	Imaging	_
33-3	5684-5688	data	_
33-4	5689-5693	were	_
33-5	5694-5703	collected	_
33-6	5704-5709	using	_
33-7	5710-5711	a	_
33-8	5712-5715	3.0	http://maven.renci.org/NeuroBridge/neurobridge#Thing
33-9	5716-5721	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalFinding
33-10	5722-5729	General	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalFinding
33-11	5730-5738	Electric	_
33-12	5739-5740	(	_
33-13	5741-5743	3T	_
33-14	5744-5746	GE	_
33-15	5747-5748	)	_
33-16	5749-5754	short	_
33-17	5755-5759	bore	_
33-18	5760-5768	Excite-2	_
33-19	5769-5775	system	_
33-20	5776-5780	with	_
33-21	5781-5783	an	_
33-22	5784-5797	eight-channel	_
33-23	5798-5809	phase-array	_
33-24	5810-5814	head	_
33-25	5815-5819	coil	_
33-26	5820-5821	.	_

34-1	5822-5827	Eight	_
34-2	5828-5842	high-bandwidth	_
34-3	5843-5852	receivers	_
34-4	5853-5856	for	_
34-5	5857-5868	ultra-short	_
34-6	5869-5879	repetition	_
34-7	5880-5884	time	_
34-8	5885-5886	(	_
34-9	5887-5889	TR	_
34-10	5890-5891	)	_
34-11	5892-5899	reduced	_
34-12	5900-5906	signal	_
34-13	5907-5918	distortions	_
34-14	5919-5922	and	_
34-15	5923-5930	dropout	_
34-16	5931-5932	.	_

35-1	5933-5948	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
35-2	5949-5952	T1-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-3	5953-5961	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-4	5962-5970	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-5	5971-5976	using	_
35-6	5977-5978	a	_
35-7	5979-5989	sagittally	_
35-8	5990-5998	acquired	_
35-9	5999-6006	spoiled	_
35-10	6007-6015	gradient	_
35-11	6016-6024	recalled	_
35-12	6025-6033	sequence	_
35-13	6034-6035	(	_
35-14	6036-6041	field	_
35-15	6042-6044	of	_
35-16	6045-6049	view	_
35-17	6050-6051	[	_
35-18	6052-6055	FOV	_
35-19	6056-6057	]	_
35-20	6058-6062	24cm	_
35-21	6063-6064	,	_
35-22	6065-6068	256	_
35-23	6069-6070	×	_
35-24	6071-6074	256	_
35-25	6075-6076	×	_
35-26	6077-6080	192	_
35-27	6081-6087	matrix	_
35-28	6088-6089	,	_
35-29	6090-6093	.94	_
35-30	6094-6095	×	_
35-31	6096-6099	.94	_
35-32	6100-6101	×	_
35-33	6102-6105	1mm	_
35-34	6106-6112	voxels	_
35-35	6113-6114	,	_
35-36	6115-6118	176	_
35-37	6119-6125	slices	_
35-38	6126-6127	,	_
35-39	6128-6138	repetition	_
35-40	6139-6148	time=20ms	_
35-41	6149-6150	,	_
35-42	6151-6155	echo	_
35-43	6156-6166	time=4.8ms	_
35-44	6167-6168	;	_
35-45	6169-6173	flip	_
35-46	6174-6179	angle	_
35-47	6180-6183	12°	_
35-48	6184-6185	,	_
35-49	6186-6190	7:26	_
35-50	6191-6198	minutes	_
35-51	6199-6200	)	_
35-52	6201-6202	.	_

36-1	6203-6208	Field	_
36-2	6209-6213	maps	_
36-3	6214-6218	were	_
36-4	6219-6227	acquired	_
36-5	6228-6230	to	_
36-6	6231-6237	assess	_
36-7	6238-6243	field	_
36-8	6244-6259	inhomogeneities	_
36-9	6260-6263	and	_
36-10	6264-6270	signal	_
36-11	6271-6278	dropout	_
36-12	6279-6283	with	_
36-13	6284-6287	two	_
36-14	6288-6297	different	_
36-15	6298-6302	echo	_
36-16	6303-6308	times	_
36-17	6309-6310	,	_
36-18	6311-6316	which	_
36-19	6317-6320	was	_
36-20	6321-6325	then	_
36-21	6326-6333	applied	_
36-22	6334-6336	to	_
36-23	6337-6340	the	_
36-24	6341-6345	BOLD	_
36-25	6346-6352	signal	_
36-26	6353-6355	to	_
36-27	6356-6364	minimize	_
36-28	6365-6372	warping	_
36-29	6373-6376	and	_
36-30	6377-6383	signal	_
36-31	6384-6392	dropouts	_
36-32	6393-6394	.	_

37-1	6395-6399	BOLD	_
37-2	6400-6406	signal	_
37-3	6407-6410	was	_
37-4	6411-6419	measured	_
37-5	6420-6424	with	_
37-6	6425-6427	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-7	6428-6429	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-8	6430-6439	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-9	6440-6447	axially	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-10	6448-6456	acquired	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-11	6457-6468	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-12	6469-6475	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-13	6476-6477	(	_
37-14	6478-6486	FOV=24cm	_
37-15	6487-6488	,	_
37-16	6489-6491	64	_
37-17	6492-6493	×	_
37-18	6494-6496	64	_
37-19	6497-6503	matrix	_
37-20	6504-6505	,	_
37-21	6506-6510	3.75	_
37-22	6511-6512	×	_
37-23	6513-6517	3.75	_
37-24	6518-6519	×	_
37-25	6520-6525	3.8mm	_
37-26	6526-6532	voxels	_
37-27	6533-6534	,	_
37-28	6535-6537	32	_
37-29	6538-6544	slices	_
37-30	6545-6546	,	_
37-31	6547-6551	echo	_
37-32	6552-6561	time=30ms	_
37-33	6562-6563	,	_
37-34	6564-6574	repetition	_
37-35	6575-6587	time=2,000ms	_
37-36	6588-6589	,	_
37-37	6590-6594	flip	_
37-38	6595-6600	angle	_
37-39	6601-6604	90°	_
37-40	6605-6606	,	_
37-41	6607-6611	task	_
37-42	6612-6616	time	_
37-43	6617-6618	:	_
37-44	6619-6623	8:32	_
37-45	6624-6625	)	_
37-46	6626-6627	.	_

38-1	6628-6632	Task	_
38-2	6633-6640	stimuli	_
38-3	6641-6645	were	_
38-4	6646-6660	back-projected	_
38-5	6661-6665	from	_
38-6	6666-6667	a	_
38-7	6668-6674	laptop	_
38-8	6675-6677	to	_
38-9	6678-6679	a	_
38-10	6680-6686	screen	_
38-11	6687-6689	at	_
38-12	6690-6693	the	_
38-13	6694-6698	foot	_
38-14	6699-6701	of	_
38-15	6702-6705	the	_
38-16	6706-6713	scanner	_
38-17	6714-6719	using	_
38-18	6720-6722	an	_
38-19	6723-6729	angled	_
38-20	6730-6736	mirror	_
38-21	6737-6745	attached	_
38-22	6746-6748	to	_
38-23	6749-6752	the	_
38-24	6753-6757	head	_
38-25	6758-6762	coil	_
38-26	6763-6764	.	_

39-1	6765-6769	Task	_
39-2	6770-6778	accuracy	_
39-3	6779-6782	and	_
39-4	6783-6791	reaction	_
39-5	6792-6797	times	_
39-6	6798-6802	were	_
39-7	6803-6809	logged	_
39-8	6810-6814	with	_
39-9	6815-6816	a	_
39-10	6817-6820	MRI	_
39-11	6821-6831	compatible	_
39-12	6832-6843	fiber-optic	_
39-13	6844-6852	response	_
39-14	6853-6856	box	_
39-15	6857-6858	(	_
39-16	6859-6866	Current	_
39-17	6867-6874	Designs	_
39-18	6875-6876	,	_
39-19	6877-6887	Pittsburgh	_
39-20	6888-6889	,	_
39-21	6890-6892	PA	_
39-22	6893-6894	)	_
39-23	6895-6896	.	_

40-1	6897-6901	Task	_
40-2	6902-6905	The	_
40-3	6906-6913	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-4	6914-6917	Cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-5	6918-6928	Reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-6	6929-6933	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-7	6934-6943	consisted	_
40-8	6944-6946	of	_
40-9	6947-6951	four	_
40-10	6952-6962	conditions	_
40-11	6963-6964	:	_
40-12	6965-6974	alcoholic	_
40-13	6975-6984	beverages	_
40-14	6985-6986	,	_
40-15	6987-7000	non-alcoholic	_
40-16	7001-7009	beverage	_
40-17	7010-7011	(	_
40-18	7012-7016	i.e.	_
40-19	7017-7018	,	_
40-20	7019-7026	neutral	_
40-21	7027-7031	cues	_
40-22	7032-7033	)	_
40-23	7034-7035	,	_
40-24	7036-7042	active	_
40-25	7043-7050	control	_
40-26	7051-7061	conditions	_
40-27	7062-7063	(	_
40-28	7064-7068	i.e.	_
40-29	7069-7070	,	_
40-30	7071-7080	pixilated	_
40-31	7081-7089	versions	_
40-32	7090-7092	of	_
40-33	7093-7096	the	_
40-34	7097-7105	beverage	_
40-35	7106-7112	images	_
40-36	7113-7114	)	_
40-37	7115-7116	,	_
40-38	7117-7120	and	_
40-39	7121-7129	fixation	_
40-40	7130-7131	(	_
40-41	7132-7136	rest	_
40-42	7137-7138	)	_
40-43	7139-7146	periods	_
40-44	7147-7148	.	_

41-1	7149-7153	Each	_
41-2	7154-7156	of	_
41-3	7157-7160	the	_
41-4	7161-7162	4	_
41-5	7163-7173	conditions	_
41-6	7174-7183	consisted	_
41-7	7184-7186	of	_
41-8	7187-7189	22	_
41-9	7190-7197	stimuli	_
41-10	7198-7202	each	_
41-11	7203-7212	presented	_
41-12	7213-7217	four	_
41-13	7218-7223	times	_
41-14	7224-7226	on	_
41-15	7227-7228	a	_
41-16	7229-7235	laptop	_
41-17	7236-7241	using	_
41-18	7242-7249	E-Prime	_
41-19	7250-7251	(	_
41-20	7252-7262	Pittsburgh	_
41-21	7263-7264	,	_
41-22	7265-7267	PA	_
41-23	7268-7269	)	_
41-24	7270-7271	.	_

42-1	7272-7279	Stimuli	_
42-2	7280-7282	in	_
42-3	7283-7287	this	_
42-4	7288-7301	event-related	_
42-5	7302-7306	task	_
42-6	7307-7311	were	_
42-7	7312-7321	presented	_
42-8	7322-7334	sequentially	_
42-9	7335-7337	in	_
42-10	7338-7355	pseudo-randomized	_
42-11	7356-7361	order	_
42-12	7362-7363	,	_
42-13	7364-7368	each	_
42-14	7369-7372	for	_
42-15	7373-7376	750	_
42-16	7377-7379	ms	_
42-17	7380-7384	with	_
42-18	7385-7386	a	_
42-19	7387-7391	1250	_
42-20	7392-7394	ms	_
42-21	7395-7409	inter-stimulus	_
42-22	7410-7418	interval	_
42-23	7419-7420	,	_
42-24	7421-7430	resulting	_
42-25	7431-7433	in	_
42-26	7434-7435	a	_
42-27	7436-7440	task	_
42-28	7441-7449	duration	_
42-29	7450-7452	of	_
42-30	7453-7454	8	_
42-31	7455-7462	minutes	_
42-32	7463-7466	and	_
42-33	7467-7469	32	_
42-34	7470-7477	seconds	_
42-35	7478-7479	(	_
42-36	7480-7486	Figure	_
42-37	7487-7488	1	_
42-38	7489-7490	)	_
42-39	7491-7492	.	_

43-1	7493-7500	Alcohol	_
43-2	7501-7504	and	_
43-3	7505-7516	non-alcohol	_
43-4	7517-7525	beverage	_
43-5	7526-7533	stimuli	_
43-6	7534-7538	were	_
43-7	7539-7549	previously	_
43-8	7550-7562	standardized	_
43-9	7563-7567	with	_
43-10	7568-7569	a	_
43-11	7570-7582	non-drinking	_
43-12	7583-7588	youth	_
43-13	7589-7595	sample	_
43-14	7596-7598	to	_
43-15	7599-7608	ascertain	_
43-16	7609-7617	adequate	_
43-17	7618-7632	identification	_
43-18	7633-7634	,	_
43-19	7635-7638	and	_
43-20	7639-7649	comparable	_
43-21	7650-7657	valence	_
43-22	7658-7659	,	_
43-23	7660-7667	arousal	_
43-24	7668-7669	,	_
43-25	7670-7673	and	_
43-26	7674-7680	visual	_
43-27	7681-7696	characteristics	_
43-28	7697-7704	between	_
43-29	7705-7708	the	_
43-30	7709-7712	two	_
43-31	7713-7723	conditions	_
43-32	7724-7725	.	_

44-1	7726-7738	Standardized	_
44-2	7739-7751	instructions	_
44-3	7752-7755	and	_
44-4	7756-7757	a	_
44-5	7758-7766	practice	_
44-6	7767-7774	version	_
44-7	7775-7777	of	_
44-8	7778-7781	the	_
44-9	7782-7786	task	_
44-10	7787-7791	were	_
44-11	7792-7805	administrated	_
44-12	7806-7813	outside	_
44-13	7814-7817	the	_
44-14	7818-7825	scanner	_
44-15	7826-7827	.	_

45-1	7828-7830	In	_
45-2	7831-7834	the	_
45-3	7835-7842	scanner	_
45-4	7843-7844	,	_
45-5	7845-7857	participants	_
45-6	7858-7862	were	_
45-7	7863-7873	instructed	_
45-8	7874-7876	to	_
45-9	7877-7885	indicate	_
45-10	7886-7889	the	_
45-11	7890-7897	valence	_
45-12	7898-7899	(	_
45-13	7900-7904	i.e.	_
45-14	7905-7906	,	_
45-15	7907-7914	dislike	_
45-16	7915-7916	,	_
45-17	7917-7924	neutral	_
45-18	7925-7926	,	_
45-19	7927-7931	like	_
45-20	7932-7933	)	_
45-21	7934-7936	of	_
45-22	7937-7941	each	_
45-23	7942-7950	stimulus	_
45-24	7951-7955	with	_
45-25	7956-7961	their	_
45-26	7962-7969	fingers	_
45-27	7970-7975	using	_
45-28	7976-7977	a	_
45-29	7978-7984	button	_
45-30	7985-7988	box	_
45-31	7989-7990	.	_

46-1	7991-8003	Participants	_
46-2	8004-8005	’	_
46-3	8006-8015	responses	_
46-4	8016-8019	and	_
46-5	8020-8028	reaction	_
46-6	8029-8034	times	_
46-7	8035-8039	were	_
46-8	8040-8046	logged	_
46-9	8047-8052	while	_
46-10	8053-8063	completing	_
46-11	8064-8067	the	_
46-12	8068-8072	task	_
46-13	8073-8079	inside	_
46-14	8080-8083	the	_
46-15	8084-8091	scanner	_
46-16	8092-8093	.	_

47-1	8094-8098	BOLD	_
47-2	8099-8107	response	_
47-3	8108-8114	signal	_
47-4	8115-8121	change	_
47-5	8122-8128	during	_
47-6	8129-8136	viewing	_
47-7	8137-8139	of	_
47-8	8140-8143	the	_
47-9	8144-8151	alcohol	_
47-10	8152-8159	picture	_
47-11	8160-8164	cues	_
47-12	8165-8170	minus	_
47-13	8171-8178	neutral	_
47-14	8179-8186	picture	_
47-15	8187-8191	cues	_
47-16	8192-8198	served	_
47-17	8199-8201	as	_
47-18	8202-8205	the	_
47-19	8206-8213	outcome	_
47-20	8214-8221	measure	_
47-21	8222-8224	of	_
47-22	8225-8233	interest	_
47-23	8234-8235	.	_

48-1	8236-8237	A	_
48-2	8238-8246	positive	_
48-3	8247-8251	BOLD	_
48-4	8252-8260	response	_
48-5	8261-8269	contrast	_
48-6	8270-8273	was	_
48-7	8274-8285	interpreted	_
48-8	8286-8288	as	_
48-9	8289-8296	greater	_
48-10	8297-8307	activation	_
48-11	8308-8310	to	_
48-12	8311-8320	alcoholic	_
48-13	8321-8329	beverage	_
48-14	8330-8334	cues	_
48-15	8335-8338	vs.	_
48-16	8339-8346	neutral	_
48-17	8347-8351	cues	_
48-18	8352-8353	;	_
48-19	8354-8355	a	_
48-20	8356-8364	negative	_
48-21	8365-8369	BOLD	_
48-22	8370-8378	response	_
48-23	8379-8387	contrast	_
48-24	8388-8391	was	_
48-25	8392-8403	interpreted	_
48-26	8404-8406	as	_
48-27	8407-8414	greater	_
48-28	8415-8425	activation	_
48-29	8426-8428	to	_
48-30	8429-8436	neutral	_
48-31	8437-8441	cues	_
48-32	8442-8445	vs.	_
48-33	8446-8455	alcoholic	_
48-34	8456-8464	beverage	_
48-35	8465-8469	cues	_
48-36	8470-8471	.	_

49-1	8472-8477	Image	_
49-2	8478-8488	Processing	_
49-3	8489-8496	Imaging	_
49-4	8497-8501	data	_
49-5	8502-8505	was	_
49-6	8506-8514	analyzed	_
49-7	8515-8520	using	_
49-8	8521-8524	the	_
49-9	8525-8533	Analysis	_
49-10	8534-8536	of	_
49-11	8537-8547	Functional	_
49-12	8548-8559	NeuroImages	_
49-13	8560-8561	(	_
49-14	8562-8566	AFNI	_
49-15	8567-8568	)	_
49-16	8569-8577	software	_
49-17	8578-8579	.	_

50-1	8580-8589	Artifacts	_
50-2	8590-8593	and	_
50-3	8594-8602	abnormal	_
50-4	8603-8610	signals	_
50-5	8611-8615	were	_
50-6	8616-8623	removed	_
50-7	8624-8627	and	_
50-8	8628-8632	time	_
50-9	8633-8639	series	_
50-10	8640-8644	data	_
50-11	8645-8649	were	_
50-12	8650-8660	temporally	_
50-13	8661-8668	aligned	_
50-14	8669-8672	and	_
50-15	8673-8686	co-registered	_
50-16	8687-8689	to	_
50-17	8690-8691	a	_
50-18	8692-8701	maximally	_
50-19	8702-8708	stable	_
50-20	8709-8713	base	_
50-21	8714-8720	volume	_
50-22	8721-8725	with	_
50-23	8726-8728	an	_
50-24	8729-8737	iterated	_
50-25	8738-8743	least	_
50-26	8744-8751	squares	_
50-27	8752-8761	algorithm	_
50-28	8762-8763	.	_

51-1	8764-8768	Each	_
51-2	8769-8779	individual	_
51-3	8780-8781	’	_
51-4	8782-8783	s	_
51-5	8784-8794	functional	_
51-6	8795-8798	and	_
51-7	8799-8809	anatomical	_
51-8	8810-8814	data	_
51-9	8815-8819	sets	_
51-10	8820-8824	were	_
51-11	8825-8838	co-registered	_
51-12	8839-8842	and	_
51-13	8843-8849	warped	_
51-14	8850-8852	to	_
51-15	8853-8865	standardized	_
51-16	8866-8875	Talairach	_
51-17	8876-8881	space	_
51-18	8882-8884	to	_
51-19	8885-8891	reduce	_
51-20	8892-8899	effects	_
51-21	8900-8902	of	_
51-22	8903-8913	anatomical	_
51-23	8914-8925	variability	_
51-24	8926-8927	.	_

52-1	8928-8938	Functional	_
52-2	8939-8943	data	_
52-3	8944-8948	were	_
52-4	8949-8958	resampled	_
52-5	8959-8963	into	_
52-6	8964-8973	isotropic	_
52-7	8974-8980	voxels	_
52-8	8981-8982	(	_
52-9	8983-8984	3	_
52-10	8985-8988	mm3	_
52-11	8989-8990	)	_
52-12	8991-8992	,	_
52-13	8993-8996	and	_
52-14	8997-9004	spatial	_
52-15	9005-9014	smoothing	_
52-16	9015-9018	was	_
52-17	9019-9026	applied	_
52-18	9027-9032	using	_
52-19	9033-9034	a	_
52-20	9035-9043	Gaussian	_
52-21	9044-9050	filter	_
52-22	9051-9052	(	_
52-23	9053-9063	full-width	_
52-24	9064-9068	half	_
52-25	9069-9076	maximum	_
52-26	9077-9078	5	_
52-27	9079-9081	mm	_
52-28	9082-9083	)	_
52-29	9084-9085	.	_

53-1	9086-9092	Motion	_
53-2	9093-9094	(	_
53-3	9095-9099	i.e.	_
53-4	9100-9101	,	_
53-5	9102-9107	three	_
53-6	9108-9118	rotational	_
53-7	9119-9122	and	_
53-8	9123-9128	three	_
53-9	9129-9135	linear	_
53-10	9136-9148	displacement	_
53-11	9149-9159	parameters	_
53-12	9160-9161	)	_
53-13	9162-9165	was	_
53-14	9166-9175	estimated	_
53-15	9176-9179	for	_
53-16	9180-9184	each	_
53-17	9185-9196	participant	_
53-18	9197-9200	and	_
53-19	9201-9205	used	_
53-20	9206-9208	to	_
53-21	9209-9216	control	_
53-22	9217-9220	for	_
53-23	9221-9233	task-related	_
53-24	9234-9242	analyses	_
53-25	9243-9244	.	_

54-1	9245-9247	An	_
54-2	9248-9257	automated	_
54-3	9258-9265	program	_
54-4	9266-9274	detected	_
54-5	9275-9283	outliers	_
54-6	9284-9286	in	_
54-7	9287-9290	the	_
54-8	9291-9294	six	_
54-9	9295-9301	motion	_
54-10	9302-9312	parameters	_
54-11	9313-9314	;	_
54-12	9315-9326	time-series	_
54-13	9327-9331	data	_
54-14	9332-9336	with	_
54-15	9337-9348	significant	_
54-16	9349-9357	outliers	_
54-17	9358-9362	were	_
54-18	9363-9371	despiked	_
54-19	9372-9374	or	_
54-20	9375-9383	censored	_
54-21	9384-9385	(	_
54-22	9386-9390	i.e.	_
54-23	9391-9392	,	_
54-24	9393-9400	removed	_
54-25	9401-9405	from	_
54-26	9406-9413	further	_
54-27	9414-9424	processing	_
54-28	9425-9426	)	_
54-29	9427-9428	.	_

55-1	9429-9431	No	_
55-2	9432-9443	participant	_
55-3	9444-9447	had	_
55-4	9448-9450	15	_
55-5	9451-9452	%	_
55-6	9453-9455	or	_
55-7	9456-9460	more	_
55-8	9461-9463	of	_
55-9	9464-9475	repetitions	_
55-10	9476-9484	censored	_
55-11	9485-9486	.	_

56-1	9487-9500	Deconvolution	_
56-2	9501-9504	was	_
56-3	9505-9514	conducted	_
56-4	9515-9517	on	_
56-5	9518-9529	time-series	_
56-6	9530-9534	data	_
56-7	9535-9539	with	_
56-8	9540-9541	a	_
56-9	9542-9551	reference	_
56-10	9552-9560	function	_
56-11	9561-9565	that	_
56-12	9566-9575	convolved	_
56-13	9576-9579	the	_
56-14	9580-9590	behavioral	_
56-15	9591-9598	stimuli	_
56-16	9599-9607	response	_
56-17	9608-9612	time	_
56-18	9613-9617	with	_
56-19	9618-9620	an	_
56-20	9621-9626	ideal	_
56-21	9627-9638	hemodynamic	_
56-22	9639-9647	response	_
56-23	9648-9653	model	_
56-24	9654-9655	,	_
56-25	9656-9665	covarying	_
56-26	9666-9669	for	_
56-27	9670-9676	linear	_
56-28	9677-9683	trends	_
56-29	9684-9687	and	_
56-30	9688-9694	motion	_
56-31	9695-9705	correction	_
56-32	9706-9716	parameters	_
56-33	9717-9718	.	_

57-1	9719-9726	Results	_
57-2	9727-9729	of	_
57-3	9730-9733	the	_
57-4	9734-9741	general	_
57-5	9742-9748	linear	_
57-6	9749-9754	model	_
57-7	9755-9763	included	_
57-8	9764-9765	,	_
57-9	9766-9769	for	_
57-10	9770-9774	each	_
57-11	9775-9780	voxel	_
57-12	9781-9782	,	_
57-13	9783-9784	1	_
57-14	9785-9786	)	_
57-15	9787-9788	a	_
57-16	9789-9792	fit	_
57-17	9793-9804	coefficient	_
57-18	9805-9809	that	_
57-19	9810-9821	represented	_
57-20	9822-9828	change	_
57-21	9829-9831	in	_
57-22	9832-9838	signal	_
57-23	9839-9846	between	_
57-24	9847-9854	alcohol	_
57-25	9855-9863	beverage	_
57-26	9864-9872	pictures	_
57-27	9873-9878	minus	_
57-28	9879-9885	active	_
57-29	9886-9893	control	_
57-30	9894-9895	,	_
57-31	9896-9897	2	_
57-32	9898-9899	)	_
57-33	9900-9910	percentage	_
57-34	9911-9917	signal	_
57-35	9918-9924	change	_
57-36	9925-9926	(	_
57-37	9927-9931	i.e.	_
57-38	9932-9933	,	_
57-39	9934-9942	contrast	_
57-40	9943-9950	between	_
57-41	9951-9958	alcohol	_
57-42	9959-9962	and	_
57-43	9963-9970	neutral	_
57-44	9971-9978	picture	_
57-45	9979-9982	cue	_
57-46	9983-9989	trials	_
57-47	9990-9991	)	_
57-48	9992-9995	and	_
57-49	9996-9997	3	_
57-50	9998-9999	)	_
57-51	10000-10009	threshold	_
57-52	10010-10020	statistics	_
57-53	10021-10022	.	_

58-1	10023-10034	Statistical	_
58-2	10035-10043	Analysis	_
58-3	10044-10048	fMRI	_
58-4	10049-10053	BOLD	_
58-5	10054-10056	To	_
58-6	10057-10061	test	_
58-7	10062-10065	the	_
58-8	10066-10070	dual	_
58-9	10071-10081	hypotheses	_
58-10	10082-10086	that	_
58-11	10087-10088	1	_
58-12	10089-10090	)	_
58-13	10091-10093	no	_
58-14	10094-10105	differences	_
58-15	10106-10108	in	_
58-16	10109-10113	BOLD	_
58-17	10114-10124	activation	_
58-18	10125-10127	to	_
58-19	10128-10135	alcohol	_
58-20	10136-10139	vs.	_
58-21	10140-10147	neutral	_
58-22	10148-10155	picture	_
58-23	10156-10160	cues	_
58-24	10161-10166	would	_
58-25	10167-10169	be	_
58-26	10170-10178	detected	_
58-27	10179-10186	between	_
58-28	10187-10191	risk	_
58-29	10192-10198	groups	_
58-30	10199-10201	at	_
58-31	10202-10210	baseline	_
58-32	10211-10214	and	_
58-33	10215-10216	2	_
58-34	10217-10218	)	_
58-35	10219-10228	high-risk	_
58-36	10229-10241	participants	_
58-37	10242-10247	would	_
58-38	10248-10255	exhibit	_
58-39	10256-10265	increased	_
58-40	10266-10276	activation	_
58-41	10277-10279	to	_
58-42	10280-10287	alcohol	_
58-43	10288-10291	vs.	_
58-44	10292-10299	neutral	_
58-45	10300-10307	picture	_
58-46	10308-10312	cues	_
58-47	10313-10318	after	_
58-48	10319-10332	transitioning	_
58-49	10333-10337	into	_
58-50	10338-10345	alcohol	_
58-51	10346-10349	use	_
58-52	10350-10352	at	_
58-53	10353-10362	follow-up	_
58-54	10363-10364	,	_
58-55	10365-10366	a	_
58-56	10367-10373	single	_
58-57	10374-10385	whole-brain	_
58-58	10386-10397	group-level	_
58-59	10398-10404	linear	_
58-60	10405-10410	mixed	_
58-61	10411-10418	effects	_
58-62	10419-10424	model	_
58-63	10425-10428	was	_
58-64	10429-10438	conducted	_
58-65	10439-10441	in	_
58-66	10442-10446	AFNI	_
58-67	10447-10448	(	_
58-68	10449-10454	3dLME	_
58-69	10455-10456	)	_
58-70	10457-10458	.	_

59-1	10459-10462	The	_
59-2	10463-10468	model	_
59-3	10469-10477	included	_
59-4	10478-10481	two	_
59-5	10482-10492	covariates	_
59-6	10493-10494	(	_
59-7	10495-10498	age	_
59-8	10499-10502	and	_
59-9	10503-10508	total	_
59-10	10509-10515	number	_
59-11	10516-10518	of	_
59-12	10519-10525	drinks	_
59-13	10526-10534	consumed	_
59-14	10535-10537	in	_
59-15	10538-10541	the	_
59-16	10542-10546	past	_
59-17	10547-10551	year	_
59-18	10552-10553	)	_
59-19	10554-10555	,	_
59-20	10556-10559	one	_
59-21	10560-10566	random	_
59-22	10567-10573	factor	_
59-23	10574-10575	(	_
59-24	10576-10588	participants	_
59-25	10589-10590	)	_
59-26	10591-10592	,	_
59-27	10593-10596	one	_
59-28	10597-10609	fixed-effect	_
59-29	10610-10624	within-subject	_
59-30	10625-10634	predictor	_
59-31	10635-10636	(	_
59-32	10637-10641	time	_
59-33	10642-10643	:	_
59-34	10644-10652	baseline	_
59-35	10653-10656	and	_
59-36	10657-10666	follow-up	_
59-37	10667-10668	)	_
59-38	10669-10670	,	_
59-39	10671-10676	three	_
59-40	10677-10688	dichotomous	_
59-41	10689-10702	fixed-effects	_
59-42	10703-10719	between-subjects	_
59-43	10720-10730	predictors	_
59-44	10731-10732	(	_
59-45	10733-10739	family	_
59-46	10740-10747	history	_
59-47	10748-10749	,	_
59-48	10750-10753	sex	_
59-49	10754-10755	,	_
59-50	10756-10768	early-dating	_
59-51	10769-10776	history	_
59-52	10777-10778	)	_
59-53	10779-10780	,	_
59-54	10781-10784	and	_
59-55	10785-10797	interactions	_
59-56	10798-10803	among	_
59-57	10804-10807	the	_
59-58	10808-10812	four	_
59-59	10813-10823	predictors	_
59-60	10824-10825	.	_

60-1	10826-10830	Mean	_
60-2	10831-10842	activations	_
60-3	10843-10847	from	_
60-4	10848-10858	functional	_
60-5	10859-10867	clusters	_
60-6	10868-10872	that	_
60-7	10873-10879	showed	_
60-8	10880-10891	significant	_
60-9	10892-10903	interaction	_
60-10	10904-10911	effects	_
60-11	10912-10916	were	_
60-12	10917-10924	extract	_
60-13	10925-10926	(	_
60-14	10927-10937	3dROIstats	_
60-15	10938-10939	)	_
60-16	10940-10943	for	_
60-17	10944-10948	each	_
60-18	10949-10953	time	_
60-19	10954-10959	point	_
60-20	10960-10961	(	_
60-21	10962-10966	i.e.	_
60-22	10967-10968	,	_
60-23	10969-10971	at	_
60-24	10972-10980	baseline	_
60-25	10981-10984	and	_
60-26	10985-10994	follow-up	_
60-27	10995-10996	)	_
60-28	10997-11000	and	_
60-29	11001-11006	group	_
60-30	11007-11008	(	_
60-31	11009-11013	e.g.	_
60-32	11014-11015	,	_
60-33	11016-11019	FHN	_
60-34	11020-11023	and	_
60-35	11024-11027	FHP	_
60-36	11028-11029	)	_
60-37	11030-11033	and	_
60-38	11034-11041	graphed	_
60-39	11042-11047	using	_
60-40	11048-11057	Microsoft	_
60-41	11058-11063	Excel	_
60-42	11064-11065	.	_

61-1	11066-11072	Graphs	_
61-2	11073-11077	were	_
61-3	11078-11086	visually	_
61-4	11087-11096	inspected	_
61-5	11097-11100	for	_
61-6	11101-11112	qualitative	_
61-7	11113-11124	description	_
61-8	11125-11127	of	_
61-9	11128-11135	signage	_
61-10	11136-11137	(	_
61-11	11138-11142	i.e.	_
61-12	11143-11144	,	_
61-13	11145-11153	positive	_
61-14	11154-11156	or	_
61-15	11157-11165	negative	_
61-16	11166-11176	activation	_
61-17	11177-11178	)	_
61-18	11179-11193	directionality	_
61-19	11194-11195	(	_
61-20	11196-11200	e.g.	_
61-21	11201-11202	,	_
61-22	11203-11212	increased	_
61-23	11213-11215	or	_
61-24	11216-11225	decreased	_
61-25	11226-11230	over	_
61-26	11231-11235	time	_
61-27	11236-11237	)	_
61-28	11238-11239	.	_

62-1	11240-11242	To	_
62-2	11243-11250	control	_
62-3	11251-11254	for	_
62-4	11255-11263	multiple	_
62-5	11264-11275	comparisons	_
62-6	11276-11279	and	_
62-7	11280-11284	Type	_
62-8	11285-11286	I	_
62-9	11287-11292	error	_
62-10	11293-11294	,	_
62-11	11295-11300	noise	_
62-12	11301-11311	smoothness	_
62-13	11312-11314	in	_
62-14	11315-11318	the	_
62-15	11319-11320	x	_
62-16	11321-11322	,	_
62-17	11323-11324	y	_
62-18	11325-11326	,	_
62-19	11327-11330	and	_
62-20	11331-11332	z	_
62-21	11333-11343	dimensions	_
62-22	11344-11347	was	_
62-23	11348-11353	first	_
62-24	11354-11363	estimated	_
62-25	11364-11365	(	_
62-26	11366-11373	3dFWHMx	_
62-27	11374-11375	)	_
62-28	11376-11380	with	_
62-29	11381-11382	a	_
62-30	11383-11391	Gaussian	_
62-31	11392-11395	and	_
62-32	11396-11410	mono-spherical	_
62-33	11411-11426	autocorrelation	_
62-34	11427-11435	function	_
62-35	11436-11437	(	_
62-36	11438-11441	acf	_
62-37	11442-11443	)	_
62-38	11444-11445	.	_

63-1	11446-11456	Parameters	_
63-2	11457-11461	from	_
63-3	11462-11466	this	_
63-4	11467-11472	model	_
63-5	11473-11477	were	_
63-6	11478-11482	then	_
63-7	11483-11490	entered	_
63-8	11491-11495	into	_
63-9	11496-11501	Monte	_
63-10	11502-11507	Carlo	_
63-11	11508-11519	simulations	_
63-12	11520-11521	(	_
63-13	11522-11532	3dClustSim	_
63-14	11533-11534	)	_
63-15	11535-11539	that	_
63-16	11540-11549	accounted	_
63-17	11550-11553	for	_
63-18	11554-11557	the	_
63-19	11558-11567	estimated	_
63-20	11568-11577	smoothing	_
63-21	11578-11580	to	_
63-22	11581-11590	determine	_
63-23	11591-11598	cluster	_
63-24	11599-11603	size	_
63-25	11604-11614	thresholds	_
63-26	11615-11619	that	_
63-27	11620-11623	met	_
63-28	11624-11627	the	_
63-29	11628-11637	following	_
63-30	11638-11646	criteria	_
63-31	11647-11648	:	_
63-32	11649-11657	bi-sided	_
63-33	11658-11670	thresholding	_
63-34	11671-11672	,	_
63-35	11673-11686	first-nearest	_
63-36	11687-11695	neighbor	_
63-37	11696-11706	clustering	_
63-38	11707-11708	,	_
63-39	11709-11720	uncorrected	_
63-40	11721-11722	(	_
63-41	11723-11732	per-voxel	_
63-42	11733-11734	)	_
63-43	11735-11736	p	_
63-44	11737-11738	<	_
63-45	11739-11743	.001	_
63-46	11744-11745	,	_
63-47	11746-11749	and	_
63-48	11750-11759	corrected	_
63-49	11760-11761	(	_
63-50	11762-11767	whole	_
63-51	11768-11774	volume	_
63-52	11775-11776	)	_
63-53	11777-11778	α	_
63-54	11779-11783	=.05	_
63-55	11784-11785	.	_

64-1	11786-11790	Only	_
64-2	11791-11798	regions	_
64-3	11799-11803	with	_
64-4	11804-11806	11	_
64-5	11807-11809	or	_
64-6	11810-11814	more	_
64-7	11815-11825	contiguous	_
64-8	11826-11832	voxels	_
64-9	11833-11837	were	_
64-10	11838-11846	retained	_
64-11	11847-11850	for	_
64-12	11851-11865	interpretation	_
64-13	11866-11867	.	_

65-1	11868-11875	Alcohol	_
65-2	11876-11887	Consumption	_
65-3	11888-11899	Differences	_
65-4	11900-11902	in	_
65-5	11903-11912	past-year	_
65-6	11913-11918	total	_
65-7	11919-11927	drinking	_
65-8	11928-11931	and	_
65-9	11932-11946	binge-drinking	_
65-10	11947-11951	days	_
65-11	11952-11954	at	_
65-12	11955-11964	follow-up	_
65-13	11965-11967	by	_
65-14	11968-11974	family	_
65-15	11975-11982	history	_
65-16	11983-11984	,	_
65-17	11985-11988	sex	_
65-18	11989-11990	,	_
65-19	11991-11994	and	_
65-20	11995-12007	early-dating	_
65-21	12008-12015	history	_
65-22	12016-12020	were	_
65-23	12021-12027	tested	_
65-24	12028-12030	in	_
65-25	12031-12052	Wilcoxon-Mann-Whitney	_
65-26	12053-12058	tests	_
65-27	12059-12063	with	_
65-28	12064-12067	the	_
65-29	12068-12072	proc	_
65-30	12073-12081	nparlway	_
65-31	12082-12090	wilcoxon	_
65-32	12091-12098	command	_
65-33	12099-12101	in	_
65-34	12102-12105	the	_
65-35	12106-12109	SAS	_
65-36	12110-12116	Studio	_
65-37	12117-12125	software	_
65-38	12126-12127	(	_
65-39	12128-12131	SAS	_
65-40	12132-12141	Institute	_
65-41	12142-12146	Inc.	_
65-42	12147-12148	,	_
65-43	12149-12153	Cary	_
65-44	12154-12155	,	_
65-45	12156-12158	NC	_
65-46	12159-12160	,	_
65-47	12161-12164	USA	_
65-48	12165-12166	;	_
65-49	12167-12174	Version	_
65-50	12175-12178	3.5	_
65-51	12179-12180	)	_
65-52	12181-12182	.	_

66-1	12183-12204	Wilcoxon-Mann-Whitney	_
66-2	12205-12210	tests	_
66-3	12211-12215	were	_
66-4	12216-12225	conducted	_
66-5	12226-12228	to	_
66-6	12229-12236	reflect	_
66-7	12237-12240	the	_
66-8	12241-12251	non-normal	_
66-9	12252-12264	distribution	_
66-10	12265-12267	of	_
66-11	12268-12271	the	_
66-12	12272-12275	two	_
66-13	12276-12283	indices	_
66-14	12284-12286	of	_
66-15	12287-12294	alcohol	_
66-16	12295-12298	use	_
66-17	12299-12301	of	_
66-18	12302-12310	interest	_
66-19	12311-12312	.	_

67-1	12313-12316	Six	_
67-2	12317-12323	models	_
67-3	12324-12328	were	_
67-4	12329-12335	tested	_
67-5	12336-12338	in	_
67-6	12339-12344	total	_
67-7	12345-12346	;	_
67-8	12347-12350	one	_
67-9	12351-12354	for	_
67-10	12355-12359	each	_
67-11	12360-12365	group	_
67-12	12366-12367	(	_
67-13	12368-12372	i.e.	_
67-14	12373-12374	,	_
67-15	12375-12378	FHP	_
67-16	12379-12382	vs.	_
67-17	12383-12386	FHN	_
67-18	12387-12388	;	_
67-19	12389-12393	male	_
67-20	12394-12397	vs.	_
67-21	12398-12404	female	_
67-22	12405-12406	;	_
67-23	12407-12419	early-dating	_
67-24	12420-12427	history	_
67-25	12428-12431	vs.	_
67-26	12432-12441	non-early	_
67-27	12442-12448	dating	_
67-28	12449-12456	history	_
67-29	12457-12458	)	_
67-30	12459-12462	and	_
67-31	12463-12470	alcohol	_
67-32	12471-12474	use	_
67-33	12475-12480	index	_
67-34	12481-12482	(	_
67-35	12483-12487	i.e.	_
67-36	12488-12489	,	_
67-37	12490-12499	past-year	_
67-38	12500-12505	total	_
67-39	12506-12514	drinking	_
67-40	12515-12519	days	_
67-41	12520-12521	,	_
67-42	12522-12531	past-year	_
67-43	12532-12537	binge	_
67-44	12538-12546	drinking	_
67-45	12547-12551	days	_
67-46	12552-12553	)	_
67-47	12554-12555	.	_

68-1	12556-12559	The	_
68-2	12560-12572	relationship	_
68-3	12573-12580	between	_
68-4	12581-12587	recent	_
68-5	12588-12589	(	_
68-6	12590-12594	i.e.	_
68-7	12595-12596	,	_
68-8	12597-12601	past	_
68-9	12602-12606	year	_
68-10	12607-12608	)	_
68-11	12609-12616	alcohol	_
68-12	12617-12628	consumption	_
68-13	12629-12631	at	_
68-14	12632-12641	follow-up	_
68-15	12642-12645	and	_
68-16	12646-12657	alcohol-cue	_
68-17	12658-12668	reactivity	_
68-18	12669-12672	was	_
68-19	12673-12681	examined	_
68-20	12682-12684	in	_
68-21	12685-12688	two	_
68-22	12689-12695	linear	_
68-23	12696-12707	regressions	_
68-24	12708-12709	(	_
68-25	12710-12716	3dMEMA	_
68-26	12717-12718	)	_
68-27	12719-12720	.	_

69-1	12721-12723	To	_
69-2	12724-12731	examine	_
69-3	12732-12735	the	_
69-4	12736-12742	effect	_
69-5	12743-12745	of	_
69-6	12746-12753	overall	_
69-7	12754-12762	drinking	_
69-8	12763-12771	quantity	_
69-9	12772-12774	on	_
69-10	12775-12782	alcohol	_
69-11	12783-12786	cue	_
69-12	12787-12797	reactivity	_
69-13	12798-12799	,	_
69-14	12800-12803	the	_
69-15	12804-12809	first	_
69-16	12810-12816	linear	_
69-17	12817-12827	regression	_
69-18	12828-12833	model	_
69-19	12834-12838	used	_
69-20	12839-12842	the	_
69-21	12843-12848	total	_
69-22	12849-12855	number	_
69-23	12856-12858	of	_
69-24	12859-12867	standard	_
69-25	12868-12874	drinks	_
69-26	12875-12883	consumed	_
69-27	12884-12886	in	_
69-28	12887-12890	the	_
69-29	12891-12895	past	_
69-30	12896-12900	year	_
69-31	12901-12903	as	_
69-32	12904-12907	the	_
69-33	12908-12917	predictor	_
69-34	12918-12919	(	_
69-35	12920-12924	i.e.	_
69-36	12925-12926	,	_
69-37	12927-12938	independent	_
69-38	12939-12940	)	_
69-39	12941-12949	variable	_
69-40	12950-12952	of	_
69-41	12953-12961	interest	_
69-42	12962-12963	.	_

70-1	12964-12966	To	_
70-2	12967-12974	examine	_
70-3	12975-12978	the	_
70-4	12979-12985	effect	_
70-5	12986-12988	of	_
70-6	12989-12994	risky	_
70-7	12995-13003	drinking	_
70-8	13004-13012	behavior	_
70-9	13013-13015	on	_
70-10	13016-13026	activation	_
70-11	13027-13029	to	_
70-12	13030-13037	alcohol	_
70-13	13038-13045	picture	_
70-14	13046-13050	cues	_
70-15	13051-13052	,	_
70-16	13053-13056	the	_
70-17	13057-13063	number	_
70-18	13064-13066	of	_
70-19	13067-13072	binge	_
70-20	13073-13081	drinking	_
70-21	13082-13090	episodes	_
70-22	13091-13093	in	_
70-23	13094-13097	the	_
70-24	13098-13102	past	_
70-25	13103-13107	year	_
70-26	13108-13109	(	_
70-27	13110-13117	defined	_
70-28	13118-13120	as	_
70-29	13121-13122	4	_
70-30	13123-13125	or	_
70-31	13126-13130	more	_
70-32	13131-13137	drinks	_
70-33	13138-13141	per	_
70-34	13142-13150	drinking	_
70-35	13151-13159	occasion	_
70-36	13160-13163	for	_
70-37	13164-13171	females	_
70-38	13172-13175	and	_
70-39	13176-13177	5	_
70-40	13178-13180	or	_
70-41	13181-13185	more	_
70-42	13186-13192	drinks	_
70-43	13193-13196	per	_
70-44	13197-13205	drinking	_
70-45	13206-13214	occasion	_
70-46	13215-13218	for	_
70-47	13219-13224	males	_
70-48	13225-13226	)	_
70-49	13227-13233	served	_
70-50	13234-13236	as	_
70-51	13237-13240	the	_
70-52	13241-13250	predictor	_
70-53	13251-13253	of	_
70-54	13254-13262	interest	_
70-55	13263-13265	in	_
70-56	13266-13269	the	_
70-57	13270-13276	second	_
70-58	13277-13283	linear	_
70-59	13284-13294	regression	_
70-60	13295-13300	model	_
70-61	13301-13302	.	_

71-1	13303-13305	In	_
71-2	13306-13310	both	_
71-3	13311-13321	regression	_
71-4	13322-13328	models	_
71-5	13329-13330	,	_
71-6	13331-13342	whole-brain	_
71-7	13343-13347	BOLD	_
71-8	13348-13352	fMRI	_
71-9	13353-13361	response	_
71-10	13362-13364	to	_
71-11	13365-13372	alcohol	_
71-12	13373-13376	vs.	_
71-13	13377-13384	neutral	_
71-14	13385-13392	picture	_
71-15	13393-13397	cues	_
71-16	13398-13400	at	_
71-17	13401-13410	follow-up	_
71-18	13411-13417	served	_
71-19	13418-13420	as	_
71-20	13421-13424	the	_
71-21	13425-13432	outcome	_
71-22	13433-13434	(	_
71-23	13435-13439	i.e.	_
71-24	13440-13441	,	_
71-25	13442-13451	dependent	_
71-26	13452-13453	)	_
71-27	13454-13462	variable	_
71-28	13463-13465	of	_
71-29	13466-13474	interest	_
71-30	13475-13476	.	_

72-1	13477-13480	The	_
72-2	13481-13485	same	_
72-3	13486-13495	procedure	_
72-4	13496-13499	for	_
72-5	13500-13508	multiple	_
72-6	13509-13520	comparisons	_
72-7	13521-13532	corrections	_
72-8	13533-13535	as	_
72-9	13536-13541	above	_
72-10	13542-13545	was	_
72-11	13546-13554	followed	_
72-12	13555-13556	(	_
72-13	13557-13568	uncorrected	_
72-14	13569-13570	p	_
72-15	13571-13572	<	_
72-16	13573-13577	.001	_
72-17	13578-13579	,	_
72-18	13580-13589	corrected	_
72-19	13590-13591	α	_
72-20	13592-13596	=.05	_
72-21	13597-13598	,	_
72-22	13599-13600	≥	_
72-23	13601-13603	11	_
72-24	13604-13614	contiguous	_
72-25	13615-13621	voxels	_
72-26	13622-13623	)	_
72-27	13624-13625	.	_

